![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: FANCC |
Gene summary for FANCC |
![]() |
Gene information | Species | Human | Gene symbol | FANCC | Gene ID | 2176 |
Gene name | FA complementation group C | |
Gene Alias | FA3 | |
Cytomap | 9q22.32 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | A0A024R9N2 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
2176 | FANCC | CCI_1 | Human | Cervix | CC | 3.73e-22 | 9.27e-01 | 0.528 |
2176 | FANCC | CCI_2 | Human | Cervix | CC | 1.66e-20 | 1.40e+00 | 0.5249 |
2176 | FANCC | CCI_3 | Human | Cervix | CC | 1.78e-34 | 1.51e+00 | 0.516 |
2176 | FANCC | RNA-P17T-P17T-4 | Human | Lung | IAC | 1.13e-06 | 6.54e-01 | 0.343 |
2176 | FANCC | RNA-P17T-P17T-6 | Human | Lung | IAC | 1.48e-03 | 4.04e-01 | 0.3385 |
2176 | FANCC | RNA-P17T-P17T-8 | Human | Lung | IAC | 1.77e-07 | 6.15e-01 | 0.3329 |
2176 | FANCC | RNA-P23T2-P23T2-4 | Human | Lung | MIAC | 3.47e-02 | 6.90e-01 | -0.0272 |
2176 | FANCC | RNA-P6T2-P6T2-1 | Human | Lung | IAC | 1.26e-04 | 2.01e-01 | -0.0166 |
2176 | FANCC | RNA-P6T2-P6T2-3 | Human | Lung | IAC | 1.03e-05 | 2.18e-01 | -0.013 |
2176 | FANCC | RNA-P6T2-P6T2-4 | Human | Lung | IAC | 2.01e-02 | 1.65e-01 | -0.0121 |
2176 | FANCC | HTA12-23-1 | Human | Pancreas | PDAC | 1.44e-05 | 6.13e-01 | 0.3405 |
2176 | FANCC | HTA12-25-1 | Human | Pancreas | PDAC | 3.07e-08 | 6.03e-01 | 0.313 |
2176 | FANCC | HTA12-26-1 | Human | Pancreas | PDAC | 1.01e-13 | 6.52e-01 | 0.3728 |
2176 | FANCC | HTA12-29-1 | Human | Pancreas | PDAC | 5.38e-40 | 8.10e-01 | 0.3722 |
Page: 1 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000697910 | Cervix | CC | response to oxidative stress | 102/2311 | 446/18723 | 2.99e-10 | 4.36e-08 | 102 |
GO:000030210 | Cervix | CC | response to reactive oxygen species | 56/2311 | 222/18723 | 1.00e-07 | 5.25e-06 | 56 |
GO:006219710 | Cervix | CC | cellular response to chemical stress | 76/2311 | 337/18723 | 1.01e-07 | 5.25e-06 | 76 |
GO:000226210 | Cervix | CC | myeloid cell homeostasis | 43/2311 | 157/18723 | 2.66e-07 | 1.12e-05 | 43 |
GO:004887210 | Cervix | CC | homeostasis of number of cells | 61/2311 | 272/18723 | 2.17e-06 | 6.55e-05 | 61 |
GO:00988699 | Cervix | CC | cellular oxidant detoxification | 30/2311 | 101/18723 | 2.72e-06 | 7.93e-05 | 30 |
GO:003459910 | Cervix | CC | cellular response to oxidative stress | 63/2311 | 288/18723 | 3.58e-06 | 9.50e-05 | 63 |
GO:19907489 | Cervix | CC | cellular detoxification | 30/2311 | 116/18723 | 5.34e-05 | 7.94e-04 | 30 |
GO:00972379 | Cervix | CC | cellular response to toxic substance | 31/2311 | 124/18723 | 8.09e-05 | 1.10e-03 | 31 |
GO:003461410 | Cervix | CC | cellular response to reactive oxygen species | 35/2311 | 155/18723 | 2.59e-04 | 2.85e-03 | 35 |
GO:00096369 | Cervix | CC | response to toxic substance | 52/2311 | 262/18723 | 3.34e-04 | 3.52e-03 | 52 |
GO:00725939 | Cervix | CC | reactive oxygen species metabolic process | 47/2311 | 239/18723 | 7.74e-04 | 6.87e-03 | 47 |
GO:00987549 | Cervix | CC | detoxification | 33/2311 | 152/18723 | 7.97e-04 | 7.00e-03 | 33 |
GO:00987275 | Cervix | CC | maintenance of cell number | 30/2311 | 134/18723 | 7.98e-04 | 7.00e-03 | 30 |
GO:00198274 | Cervix | CC | stem cell population maintenance | 29/2311 | 131/18723 | 1.17e-03 | 9.47e-03 | 29 |
GO:0006801 | Cervix | CC | superoxide metabolic process | 17/2311 | 74/18723 | 7.73e-03 | 4.10e-02 | 17 |
GO:00069798 | Lung | IAC | response to oxidative stress | 82/2061 | 446/18723 | 1.99e-06 | 9.18e-05 | 82 |
GO:00022628 | Lung | IAC | myeloid cell homeostasis | 37/2061 | 157/18723 | 5.42e-06 | 2.09e-04 | 37 |
GO:00621978 | Lung | IAC | cellular response to chemical stress | 64/2061 | 337/18723 | 8.92e-06 | 3.01e-04 | 64 |
GO:00488728 | Lung | IAC | homeostasis of number of cells | 54/2061 | 272/18723 | 1.20e-05 | 3.64e-04 | 54 |
Page: 1 2 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FANCC | SNV | Missense_Mutation | c.547N>G | p.Leu183Val | p.L183V | Q00597 | protein_coding | tolerated(0.41) | possibly_damaging(0.592) | TCGA-43-6770-01 | Lung | lung squamous cell carcinoma | Female | <65 | I/II | Vaccine | recprame+as15 | SD | |
FANCC | SNV | Missense_Mutation | c.1550N>T | p.Glu517Val | p.E517V | Q00597 | protein_coding | tolerated(0.15) | benign(0.328) | TCGA-46-3768-01 | Lung | lung squamous cell carcinoma | Male | <65 | III/IV | Chemotherapy | carboplatin | SD | |
FANCC | SNV | Missense_Mutation | novel | c.1549G>A | p.Glu517Lys | p.E517K | Q00597 | protein_coding | tolerated(0.41) | benign(0.331) | TCGA-90-7964-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
FANCC | SNV | Missense_Mutation | rs780136692 | c.1261G>A | p.Ala421Thr | p.A421T | Q00597 | protein_coding | deleterious(0.04) | probably_damaging(0.911) | TCGA-XK-AAIW-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 9 | Unknown | Unknown | PD |
FANCC | SNV | Missense_Mutation | c.1468N>T | p.Leu490Phe | p.L490F | Q00597 | protein_coding | deleterious(0) | probably_damaging(0.964) | TCGA-BR-4201-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Chemotherapy | cisplatin | SD | |
FANCC | SNV | Missense_Mutation | c.955A>G | p.Thr319Ala | p.T319A | Q00597 | protein_coding | deleterious(0) | benign(0.437) | TCGA-CG-5721-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | SD | |
FANCC | SNV | Missense_Mutation | novel | c.866C>A | p.Ala289Asp | p.A289D | Q00597 | protein_coding | deleterious(0) | probably_damaging(0.974) | TCGA-VQ-A91D-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | fluorouracil | PD |
FANCC | deletion | Frame_Shift_Del | c.455delN | p.Asn152IlefsTer6 | p.N152Ifs*6 | Q00597 | protein_coding | TCGA-CD-A4MG-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2176 | FANCC | CLINICALLY ACTIONABLE, DNA REPAIR | MITOMYCIN | MITOMYCIN | 16243825 | |
2176 | FANCC | CLINICALLY ACTIONABLE, DNA REPAIR | CHLORAMBUCIL | CHLORAMBUCIL | 16243825 | |
2176 | FANCC | CLINICALLY ACTIONABLE, DNA REPAIR | CISPLATIN | CISPLATIN | 16243825 | |
2176 | FANCC | CLINICALLY ACTIONABLE, DNA REPAIR | MELPHALAN | MELPHALAN | 16243825 | |
2176 | FANCC | CLINICALLY ACTIONABLE, DNA REPAIR | GEMCITABINE | GEMCITABINE | 16243825 |
Page: 1 |